Narrow your search

Library

KU Leuven (6)

KBR (3)

UGent (1)

UHasselt (1)


Resource type

dissertation (5)

book (4)

periodical (1)


Language

English (9)

Dutch (1)


Year
From To Submit

2020 (1)

2015 (1)

2014 (1)

2005 (1)

2004 (2)

More...
Listing 1 - 10 of 10
Sort by

Book
Advances in infantile metabolic brain diseases
Author:
Year: 1985 Publisher: Leuven K.U.L.

Loading...
Export citation

Choose an application

Bookmark

Abstract


Dissertation
Advances in infantile metabolic brain diseases
Authors: ---
Year: 1985

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Periodical
The adventure of Blue Square and Green Square
Authors: ---
Year: 2004 Publisher: Kortenaken Aardappel Comics

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Book
Advances in infantile metaoblic brain diseases
Authors: ---
Year: 1985 Publisher: Leuven

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Book
The adventures of blue square and green Square
Authors: --- --- ---
ISBN: 9077391061 Year: 2004 Publisher: Kortenaken Aardappel Comics

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Dissertation
Congenital Disorders of Glycosylation : The Next Generation
Authors: --- --- ---
ISBN: 9789462330566 Year: 2015 Publisher: Leuven KU Leuven. Faculty of Medicine

Loading...
Export citation

Choose an application

Bookmark

Abstract

Glycosylation is one of the most abundant protein modifications found in nature. It results from a meticulously orchestrated process involving numerous proteins for the assembly and modification of oligosaccharide chains, and their attachment onto proteins and lipids. The importance of glycosylation is illustrated by a group of diseases called Congenital Disorders of Glycosylation (CDG). To date, almost 100 distinct disorders have been identified encompassing defects in N- and O-linked protein glycosylation, but also in the synthesis of GPI-anchors and glycolipids. Considering the possibility to screen for most deficiencies in protein N-glycosylation by means of isoelectric focusing of serum transferrin, the project focused on this group of disorders.The genetic heterogeneity of CDG, but also the phenotypic overlap between the different disorders is remarkable. A clinical ‘hit and run’ diagnosis forms thus rather the exception than the rule. Therefore, patients with a biochemically proven glycosylation deficiency remain often without a molecular diagnosis. In this study, we aimed to circumvent the bottleneck of a gene by gene approach through the implementation of massive parallel sequencing techniques in as well CDG research as diagnostics (Chapter 3).For the elucidation of novel CDG, whole exome sequencing was performed in 24 individuals with a presumed deficiency in the N-linked glycosylation pathway (Chapter 4 and 5). Once the genetic defect was identified, its pathogenic nature was confirmed using cell biological assays. In this way, a genetic diagnosis could be obtained in nine patients (i.e. 38%), while the most likely candidate gene is still under investigation in seven additional cases (i.e. 30%).In parallel, a targeted assay for a panel of 79 genes was developed to improve CDG diagnostics (Chapter 6). Over a period of two years, the panel was used for molecular testing in a total number of 86 patients with a presumed deficiency in the N-linked glycosylation pathway. A final molecular diagnosis could be obtained in 38 of them (i.e. 44%). Based on these results, we proposed a tentative novel flowchart wherein a patient considered to have CDG first enters a diagnostic setting for gene panel testing. A close collaboration between the diagnostic and research department would then allow those patients, in whom the culprit gene could not be identified or in whom the pathogenicity of a variant needs to be verified, to subsequently enter a research setting for further biochemical testing.During this study, mutations in MAN1B1 were identified to cause a novel CDG-II. The biochemical characteristics of the index case allowed for the rapid identification of 18 additional patients (Chapter 7). All cases displayed a similar phenotype characterized by intellectual disability, delayed motor and speech development, hypotonia, macrocephaly and truncal obesity.During the time span of this PhD project, the intracellular localization of MAN1B1 became the subject of a still ongoing debate. Indeed, besides its role in N-glycan processing, the α(1,2)-mannosidase has been proposed to act as a key factor in ER quality control by targeting terminally misfolded proteins for proteasomal degradation. Since all mediators of ERAD are assumed to reside within the ER, it only seemed natural that MAN1B1 would execute its function within the same organelle. However, today opinions are changing. While some researchers still believe that MAN1B1 resides within the ER, others are convinced that the enzyme localizes to a presumed ERQC compartments or resides within the Golgi apparatus.In Chapter 9, we could clearly demonstrate that the endogenous MAN1B1 in primary skin fibroblasts is localized within the Golgi apparatus, thereby confirming the initial –but still controversial– results of Sifers and coworkers. Our findings were further supported by the observation that MAN1B1 deficient fibroblasts display an aberrant Golgi morphology in the absence of an ER stress response (i.e. UPR or unfolded protein response) (Chapter 8 and 9).While former studies mainly focused on the effect of MAN1B1 deficiency on the fate of misfolded cargo, we investigated –with respect to the phenotype– the effect on secretory proteins that attained their native folding state (Chapter 9). In this way, we could demonstrate that MAN1B1 deficiency does not only enable the intracellular accumulation and partial secretion of nonnative proteins, but in addition impairs the anterograde trafficking of the properly folded cargo.In Chapter 10 of this manuscript, we assumed that the aforementioned accumulation of (mis-)folded proteins within the Golgi apparatus could overwhelm the capacity of the secretory pathway, thereby generating a primary Golgi stress response. Through several pilot experiments we could show that MAN1B1 deficiency generates a mild to moderate transcriptional response that was not only uniformly present among the different patients, but that also differed from the responses observed in other CDG-II cell lines. However, additional investigations are necessary to further address the extent of a possible Golgi stress response in MAN1B1-CDG and to understand how this transcriptional response might impact patient management.

Keywords


Dissertation
Voeding bij kinderen en volwassenen met glycogeenstapelingsziekte type 1 : een literatuurstudie.
Authors: --- ---
Year: 2005 Publisher: Leuven K.U.Leuven. Faculteit geneeskunde

Loading...
Export citation

Choose an application

Bookmark

Abstract

Keywords


Dissertation
Ophthalmological and electrophysiological findings in monozygotic twin sisters with phosphomannomutase 2 deficiency (PMM2-CDG) over a period of 37 years

Loading...
Export citation

Choose an application

Bookmark

Abstract

Aims Evaluating the evolution of ophthalmic findings in identical twin sisters with PMM2-CDG. Methods A clinical ophthalmic examination with vision measurement, fundoscopy and flash electroretinogram was performed at the age of 4, 18 and 41 years. Results Ophthalmic examination at the age of 4 years showed in both girls an alternating convergent squint and a saccadic pursuit, with a vision of 6/9 on both eyes measured with the Ffooks symbols test. Fundoscopy revealed a normal aspect of the optic discs, with a narrowing of the blood vessels and mild irregular pigmentation in the peripheral retina. Flash ERG of one girl showed a recognisable a, b1 and b2 wave, but with a reduction of the amplitude to less than 40 % of the normal amplitude. In the other girl, this reduced amplitude was more pronounced, but a small b1 wave for the white flash was still noticeable. At the age of 18 years, vision had remained stable. Fundus examination revealed a pink aspect of the optic discs, with moderately narrowing of the vasculature and bone spicules in the mid peripheral retina. fERG showed obvious progression with a completely extinguished trace bilaterally. At the age of 41 years, vision had slightly diminished to 6/12 in both women. Fundoscopy and electroretinogram did not show any changes. Conclusions Despite obvious deterioration on the electroretinogram between the age of 4 and 18 years, the central vision showed only a minor decrease between the age of 18 and 41 years with still a functional visual acuity.

Keywords


Dissertation
Zebrafish as a Model for Glycosylation Defects. Fishing for the Role of TMEM165
Authors: --- --- --- --- --- et al.
Year: 2014 Publisher: Leuven KU Leuven. Faculty of Medicine

Loading...
Export citation

Choose an application

Bookmark

Abstract

Congenital Disorders of Glycosylation (CDG) represent a heterogeneous group of inherited diseases characterized by defective N-and O-glycosylation and defective lipid glycosylation. Protein N-glycosylation disorders, which range in severity and systemic presentation, are traditionally divided into two groups. The largest group, type I CDG (CDG-I), results from defects in enzymes involved in either the biosynthesis of the lipid-linked oligosaccharide precursor (LLO) Glc3Man9GlcNAc2-P-P-dolichol (G3M9Gn2-P-P-Dol) or its transfer to the nascent polypeptides in the ER. The second group, type II CDG (CDG-II), results from alterations in the processing or remodeling of the protein-bound glycan chains. Type II CDG encompasses defects in glycosidases, glycosyltransferases, and sugar nucleotide transporters, but also in proteins involved in Golgi trafficking, structure, and pH homeostasis. In light of the ability of the latter group to alter the global environment necessary for proper glycosylation, such defects typically result in structural changes within multiple classes of glycans (e.g. N- and O-glycans). One particular CDG, caused by mutations in TMEM165, a transmembrane protein whose function remains elusive, is the subject of this thesis.Mutations in the protein TMEM165 (transmembrane protein 165) were recently shown to cause a novel type II CDG. Two siblings presented psychomotor retardation, dwarfism, and significant skeletal abnormalities. Isoelectric focusing of serum transferrin revealed an abnormal pattern consistent with type II CDG, prompting efforts to identify the genetic basis for the disease in these patients. Glycomic analysis of N-glycans revealed an increase in the relative abundance of undersialylated and undergalactosylated glycans. Homozygosity mapping and gene array expression profiling uncovered a homozygous, deep intronic splice mutation (c.792+182G>A) within the previously uncharacterized transmembrane protein TMEM165 in the two affected siblings. Sequencing of TMEM165 in a group of unsolved CDG-IIx patients identified three additional patients with mutations: one patient with the previously described homozygous mutation (c.792+182G>A) and two unrelated individuals with missense mutations (one homozygous for c.377G>A (p.R126H) and another compound heterozygous for c.376C>T (p.R126C) and c.911G>A (p.G304R)).The TMEM165 gene encodes a 324 amino acid protein containing 6 transmembrane-spanning domains. It is ubiquitously expressed and highly conserved within eukaryotes. TMEM165 belongs to the UPF0016 family of integral membrane proteins of unknown function. Based on predicted topology and comparative phylogeny, it is proposed to function in Golgi proton/calcium transport. Furthermore, studies in yeast have suggested that TMEM165 is a member of Golgi-localized Ca2+/H+ antiporters, and may play an important role in the maintenance of the Golgi structure and/or pH. Despite growing insight into the molecular function of TMEM165, the physiological relevance of this protein during development, particularly with regard tothe skeletal system, remains poorly understood. In an effort to improve our understanding of its physiologic and pathogenic functions, we employed a morpholino-based approach to reduce tmem165 expression in developing zebrafish.Our results indicate that this protein is essential for proper cartilage development, as tmem165-deficient embryos exhibit altered morphology of multiple craniofacial structures. In situ hybridization demonstrated that loss of Tmem165 was associated with reduced expression of the chondroitin sulfate proteoglycan aggrecan, as well as several later stage markers of both cartilage and bone maturation. These deficiencies resulted in reduced mineralization of morphant cartilages. Although the cartilage phenotypes were effectively rescued by introduction of wild type tmem165 mRNA, no recovery was observed with tmem165 mRNA bearing the R126H change found in human patients, confirming the pathogenic nature of this mutation. Mass spectrometric analyses of control and morphant embryos demonstrated that tmem165 is necessary for proper processing of N-glycans in zebrafish, a finding consistent with the CDG phenotype seen in human patients.In conclusion, the present work reports our study of the developmental impact of tmem165 deficiency in zebrafish, which establishes the first animal model for this new CDG subtype. Our analysis of tmem165 morphant embryos demonstrates that tmem165 deficiency in zebrafish results in altered N-linked glycosylation and cartilage defects. Importantly, both the morphological and biochemical phenotypes noted in the zebrafish model mirror those seen in human patients. This also unequivocally establishes the causal link between the TMEM165 defect and the disease.

Keywords

Listing 1 - 10 of 10
Sort by